Growth and Cardiometabolic Risk Among In Utero Drug Exposed Children

描述（由申请人提供）：该K01奖将允许候选人Sarah Messiah博士获得成为独立研究者所需的技能、知识和经验。利用迈阿密产前可卡因研究（MFCS， Emmalee Bandstra博士，首席研究员）的数据，Messiah博士将检查16-18岁非裔美国儿童子宫内可卡因暴露，人体测量生长和心脏代谢疾病风险因素发展之间的关系。MPCS已经收集了400多名婴儿及其母亲/替代照顾者在青春期早期的11波多领域数据，现在正在着手收集另外两波16 -18岁的数据。建议的指导研究有三个具体目的：(1)纵向比较城市、非裔美国儿童和青少年的人体测量值（身高、体重、体重指数、腰围和身体组成），这些儿童和青少年产前是否暴露于可卡因，使用先前建立的和特征良好的NIDA队列；(2)利用先前建立的、特征明确的NIDA队列，对产前暴露于或未暴露于可卡因的城市非裔美国青少年的心脏代谢危险因素（空腹血糖、胰岛素、血脂、CRP、血压）进行横断面比较；(3)在重复测量多变量分析中确定产前和产后可卡因暴露的具体影响，控制影响调节剂（尼古丁，酒精和大麻暴露，儿童和母亲的压力，焦虑和抑郁）：(a)超重和肥胖，(b)体重不足，(c) bbb30心脏代谢危险因素（通常称为“代谢综合征”）。为了实现这项研究和她的职业发展目标，Messiah博士将遵循迈阿密大学米勒医学院的职业发展计划，旨在提供4个核心能力方面的知识、技能和经验（疾病的生命过程，特别强调子宫内可卡因暴露、纵向/潜在生长分析方法、胚胎学、儿童时期心脏代谢疾病风险因素的发展以及成年后发病慢性疾病的后续风险）。拟议研究的广泛和长期目标是阐明因果和非因果联系，特别关注子宫内可卡因暴露如何改变人体测量生长的发生和轨迹，以及随后心脏代谢疾病风险因素的发展。这项调查的结果应告知物质使用和心血管研究领域，后代在怀孕期间摄入可卡因的后续风险。

DESCRIPTION (provided by applicant): This K01 award will allow the candidate, Dr. Sarah Messiah, to gain the skills, knowledge and experience required to become an independent investigator. Using data from the Miami Prenatal Cocaine Study (MFCS, Dr. Emmalee Bandstra, Principal Investigator), Dr. Messiah will examine the relationship between in utero cocaine exposure, anthropometric growth and development of cardiometabolic disease risk factors in African American children at ages 16-18. The MPCS has collected 11 prior waves of multi-domain data on over 400 infants and their mothers/alternate caregivers through early adolescence and is now embarking on 2 additional waves of data collection at ages 16 -18 years. The proposed mentored research has three specific aims: (1) To longitudinally compare anthropometric measures (height, weight, body mass index, waist circumference, and body composition) among urban, African American children and adolescents who were or were not prenatally exposed to cocaine using a previously established and well-characterized NIDA cohort; (2) To compare cardiometabolic risk factors (fasting glucose, insulin, lipids, CRP, blood pressure) cross-sectionally among urban, African American adolescents who were or were not exposed prenatally to cocaine using a previously established and well-characterized NIDA cohort; and (3) To determine the specific effects of both prenatal and postnatal exposures of cocaine in a repeated measures multivariate analysis, controlling for effect modifiers (nicotine, alcohol and marijuana exposure, stress, anxiety and depression in children and mothers) on: (a) Overweight and obesity, (b) Underweight, and (c) > 3 cardiometabolic risk factors (often referred to as "metabolic syndrome"). To achieve this research and her career development goals, Dr. Messiah will follow a career development plan at the University of Miami Miller School of Medicine, designed to provide knowledge, skills, and experience in 4 core competencies (hfe course of disease, with particular emphasis on in utero cocaine exposure, longitudinal/latent growth analytical methods, embryology, and cardiometabolic disease risk factor development in childhood and subsequent risk for adult onset chronic disease). The broad, long-term goal of the proposed research is to elucidate causal and non-causal links with a specific focus upon how in utero cocaine exposure might alter the occurrence and trajectories of anthropometric grovrth, and subsequent development of cardiometabolic disease risk factors. Findings from this investigation should inform both the fields of substance use and cardiovascular research about subsequent risks of cocaine ingestion during pregnancy in offspring.